Methods of producing human RPE cells and pharmaceutical preparations of human RPE cells

Patent metadata

Field	Value
Publication number	US-10485829-B2
Application number	US-201013510426-A
Country	US
Kind code	B2
Filing date	Nov 17, 2010
Priority date	Nov 17, 2009
Publication date	Nov 26, 2019
Grant date	Nov 26, 2019

Abstract

The present invention provides improved methods for producing retinal pigmented epithelial (RPE) cells from human embryonic stem cells, human induced pluripotent stem (iPS), human adult stem cells, human hematopoietic stem cells, human fetal stem cells, human mesenchymal stem cells, human postpartum stem cells, human multipotent stem cells, or human embryonic germ cells. The RPE cells derived from embryonic stem cells are molecularly distinct from adult and fetal-derived RPE cells, and are also distinct from embryonic stem cells. The RPE cells described herein are useful for treating retinal degenerative conditions including retinal detachment and macular degeneration.

First claim

We claim:

1. A method of producing a pharmaceutical preparation or a cryopreserved composition of human RPE cells comprising
(a) culturing human pluripotent stem cells under non-adherent conditions for 7-14 days to form cell masses;
(b) culturing the cell masses to form an adherent culture comprising human RPE cells;
(c) dissociating human RPE cells from the adherent culture;
(d) culturing said dissociated RPE cells to about 95-100% confluency and a medium pigmentation;
(e) dissociating the human RPE cells of (d);
(f) repeating steps (d) to (e) at least once;
(g) harvesting a population of said dissociated human RPE cells;
(h) detecting expression of (i) ZO-1 and (ii) Pax6 and/or MITF in an aliquot of the harvested population to partially characterize the harvested population; and
(i) formulating at least a portion of the harvested population as a pharmaceutical preparation or a cryopreserved composition of RPE cells if the harvested population is characterized as
(1) ≥95% of the cells in the harvested population are positive for PAX6 and/or MITF by immunostaining; and/or ≥95% of the cells in the harvested population are positive for PAX6 and/or bestrophin by immunostaining; and
(2) ≥95% of the cells in the harvested population are positive for ZO-1 by immunostaining; and
(3) the harvested population is negative for Oct-4, Nanog, Rex-1 and Sox2 by qPCR; and
(4) the harvested population is negative for Oct-4 and alkaline phosphatase by immunostaining;

wherein RPE cells of the harvested population survive in vivo at least about 6 months, and
wherein the culture conditions are not permissive to pluripotent stem cells.

2. The method of claim 1 , wherein said human pluripotent stem cells are selected from human induced pluripotent stem (iPS) cells, human embryonic stem (ES) cells, human adult stem cells, hematopoietic stem cells, fetal stem cells, mesenchymal stem cells, postpartum stem cells, multipotent stem cells or embryonic germ cells.

3. The method of claim 1 , wherein in step (e) the human RPE cells are dissociated using an enzyme selected from trypsin, collagenase, dispase, papain, a mixture of collagenase and dispase, and a mixture of collagenase and trypsin.

4. A pharmaceutical preparation or cryopreserved composition comprising human RPE cells prepared by the method of claim 1 .

5. The method of claim 1 , wherein the human RPE cells in the harvested population are
(1) positive for bestrophin, RPE-65, CRALBP, PEDF, PAX6 and MITF by qPCR, and/or
(2) positive for bestrophin, CRALBP, PAX6, MITF and ZO-1 by immunostaining.

6. The method of claim 1 , wherein greater than or equal to 85% of the human RPE cells in the harvested population are viable.

7. The method of claim 1 , wherein at least a portion of the harvested population is formulated as a cryopreserved composition and wherein greater than or equal to 70% of the human RPE cells therein are viable after cryopreservation.

8. The pharmaceutical preparation or cryopreserved composition of claim 4 , wherein greater than or equal to 85% of the human RPE cells are viable prior to cryopreservation and/or greater than or equal to 70% of the human RPE cells are viable after cryopreservation.

9. The pharmaceutical preparation or cryopreserved composition of claim 4 , wherein the human RPE cells are provided as a suspension of cells.

10. The pharmaceutical preparation or cryopreserved composition of claim 4 , wherein the human RPE cells are provided in a pharmaceutical preparation and are disposed on a matrix.

11. The method of claim 1 , wherein the method steps are conducted in accordance with Good Manufacturing Practices (GMP) or Good Tissue Practices (GTP).

12. The method of claim 1 , wherein the dissociated RPE cells in (d) are cultured in RPE-GM.

13. The method of claim 1 , wherein the dissociated RPE cells in (d) are cultured in RPE-MM.

Assignees

• Malcuit Christopher
• Lemieux Linda
• Holmes William
• Huertas Pedro
• Vilner Lucy
• Astellas Inst For Regenerative Medicine

Inventors

• Malcuit Christopher
• Lemieux Linda
• Holmes William
• Huertas Pedro
• Vilner Lucy

Classifications

• A61P27/02

  Ophthalmic agents · CPC title

• C12N5/0621

  Eye cells, e.g. cornea, iris pigmented cells (photoreceptors C12N5/062) · CPC title

• C12N2506/02

  from embryonic cells · CPC title

• A61K35/12 Primary

  Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K39/00) · CPC title

• A61K35/56

  Materials from animals other than mammals · CPC title